Dianthus Therapeutics | MGTA - Zinsaufwendungen Für Schuld

Aktienkurs
87.39
Täglich Wechseln
-2.43 -2.71%
Monatlich
9.77%
Jährlich
303.28%
Q2 Prognose
85.52




Zinsaufwendungen Für Schuld Veränderung Datum
Akebia Therapeutics 4.83M 359.32M 2025-12
Alaunos Therapeutics USD 1.07M 215K 2023-06
Avita Medical AUD 1.25M 100K 2025-06
Celltrion KRW 19B 1.96B 2025-06
Cspc Pharmaceutical CNY 6.76M 3.43M 2025-12
Deva Holding AS TRY 272.53M 69.04M 2023-09
Dianthus Therapeutics USD 4.44M 263K 2024-09
Divis Laboratories Ltd INR 60M 30M 2025-12
IQVIA Holdings USD 193M 4M 2025-12
Kangmei Pharma CNY 1.82M 150K 2025-09
Knight Therapeutics CAD 3.92M 1.56M 2025-12
Laboratorios Farma EUR 699K 666.2K 2025-06
Medical Developments International AUD 18K 3K 2025-06
Moderna USD 12.14B 12.13B 2025-09
Neuren Pharmaceuticals AUD 0 0 2024-06
Organigram Holdings CAD 179K 127K 2025-03
Organon & Co USD 128M 3M 2025-09
Ovoca Bio EUR 7K 6K 2022-06
Pharma Mar EUR 117K 1.24M 2025-09
Qiagen NV USD 10.14M 1.92M 2025-12
Revvity USD 23.51M 742K 2025-12
Sartorius EUR 49.5M 8.1M 2025-09
Sino Biopharmaceutical CNY 76.87M 114.23M 2024-06
Tectonic Therapeutic USD 12K 276.99M 2025-12
Tilray USD 6.7M 2.73M 2025-06
Viatris USD 119.6M 0 2025-12
Xeris Pharmaceuticals USD 7.15M 115K 2025-12
Zealand Pharma A/S 7.07M 74K 2025-12
Zz Pientze Pharmaceu CNY 46.05M 36.5M 2025-06